Zydus Wellness looks to strengthen nutrition, immunity play
Launches calcium-enriched chocolate spreads under brand Nutralite20-07-2020
20-07-2020
Bharat Biotech to Zydus: Seven Indian firms race to develop Covid vaccine
Vaccines normally require years of testing and additional time to produce at scale, but scientists are hoping to develop a coronavirus vaccine within months because of the pandemic19-07-2020
Cadila Health shares gain as Zydus drug receives nod to conduct clinical trials to treat COVID-19
Zydus received approval from COFEPRIS to conduct clinical trials in Mexico with Pegylated Interferon alpha-2b to treat novel Coronavirus.17-07-2020
Zydus begins human trials for potential coronavirus vaccine
Coronavirus vaccine update: ZyCoV-D, its plasmid DNA vaccine, was found to be safe, immunogenic and well-tolerated in the pre-clinical toxicity studies, Zydus said15-07-2020
ZYDUS WELLNESS LTD.-$ - 531335 - Disclosure On Impact Of COVID- 19 Pandemic On The Business And Operations Of Zydus Wellness Limited ('The Company').
Disclosure on impact of COVID- 19 pandemic on the Business and Operations of Zydus Wellness Limited ('the Company').13-07-2020
ZYDUS WELLNESS LTD.-$ - 531335 - Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Dhanraj P DagarDesignation :- Company Secretary and Compliance Officer13-07-2020
ZYDUS WELLNESS LTD.-$ - 531335 - Shareholding for the Period Ended June 30, 2020
Zydus Wellness Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click here10-07-2020
ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018.10-07-2020
Zydus gets Mexican regulator's approval for coronavirus drug study
Desidustat tablets to be tested for the management of coronavirus patients-the first such approval06-07-2020
ZYDUS WELLNESS LTD.-$ - 531335 - General Notice To Shareholders Of Company To Register Their Email Address And Mobile No.
General Notice to Shareholders of Company to register their email address and mobile no.04-07-2020